Neutralizing autoantibodies against IL-17A, IL-17F, and IL-22, which are present in the vast majority of APS-1 patients, significantly impair the Th17 pathway, which is crucial for mucosal fungal defense. This evidence concerns the gene IL22 and autoimmune polyendocrine syndrome type 1.